(Q37052640)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

positron emission tomography

31 December 2019

main subject

1 reference

1 reference

Giuseppe Lucio Cascini

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

C Greco

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

O Tamburrini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

8 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

121-128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18180806%20AND%20SRC:MED&resulttype=core&format=json

Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

Clinical states in prostate cancer: toward a dynamic model of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Management of the patient with a rising PSA alone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Rising prostate-specific antigen after primary prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Radiation therapy after radical prostatectomy: A review of the issues and options

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Predictors of mortality after prostate-specific antigen failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Advances in imaging in the postoperative patient with a rising prostate-specific antigen level

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Imaging of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Image analysis in patients with cancer studied with a combined PET and CT scanner

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

PET/CT: a new imaging technology in nuclear medicine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

(11)C-acetate PET in the early evaluation of prostate cancer recurrence.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Noninvasive detection of clinically occult lymph-node metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Detecting Metastatic Pelvic Lymph Nodes by <sup>18</sup>F-2-Deoxyglucose Positron Emission Tomography in Patients with Prostate-Specific Antigen Relapse after Treatment for Localized Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501028

7 January 2021